Heather Yost, PA
Medical · Watsontown, PANPI 1700038700
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 765 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 765 payments — averaging $15.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- Amgen$838
- GSK$750
- AstraZeneca$692
- plus $4K from 32 others
What the payments were for
- Food & beverage$12,174100%
- Education$470%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 147 | $2,338 |
| Novo Nordisk | 125 | $1,868 |
| Lilly USA, LLC | 119 | $1,656 |
| Amgen | 57 | $838 |
| GSK | 45 | $750 |
| AstraZeneca(2 entities) | 30 | $692 |
| Pfizer | 42 | $630 |
| Astellas Pharma US Inc | 29 | $528 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 23 | $387 |
| Merck | 23 | $325 |
| Exact Sciences | 13 | $292 |
| Novartis | 13 | $221 |
| Johnson & Johnson | 13 | $189 |
| Teva Pharmaceuticals USA, Inc. | 10 | $177 |
| Bayer | 9 | $164 |
| Phathom Pharmaceuticals, Inc. | 8 | $142 |
| Otsuka America Pharmaceutical, Inc. | 6 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $118 |
| Esperion Therapeutics, Inc. | 4 | $75 |
| Boehringer Ingelheim | 5 | $75 |
| Cequr Corporation | 2 | $73 |
| Dexcom, Inc. | 4 | $70 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $64 |
| Genentech USA, Inc. | 4 | $57 |
| E.r. Squibb & Sons, L.L.C. | 3 | $45 |
| IBSA Pharma Inc. | 2 | $41 |
| Organon | 3 | $40 |
| Neurocrine Biosciences, Inc. | 2 | $36 |
| Xeris Pharmaceuticals, Inc. | 2 | $34 |
| Avanir Pharmaceuticals, Inc. | 2 | $30 |
| Biogen | 2 | $27 |
| Corium, LLC | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Indivior Inc. | 1 | $18 |
| Radius Health, Inc. | 1 | $17 |
| Biodelivery Sciences International, Inc. | 1 | $14 |
| Neurelis, Inc. | 1 | $13 |
| Lundbeck LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,221 in reported general payments places this provider in the 95th percentile of 2,594 medical providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 82 | $92,544 |
| JardianceEmpagliflozin | 51 | $46,957 |
| EliquisApixaban | 55 | $45,183 |
| FarxigaDapagliflozin Propanediol | 36 | $44,391 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $21,056 |
| TrulicityDulaglutide | 19 | $18,360 |
| MyrbetriqMirabegron | 20 | $17,593 |
| RybelsusSemaglutide | 19 | $16,593 |
| MounjaroTirzepatide | 14 | $15,154 |
| XareltoRivaroxaban | 14 | $12,611 |
| LinzessLinaclotide | 14 | $10,202 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $9,709 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $9,309 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $7,665 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,613 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,868 | $109,137101 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $692 | $54,10150 claims |
| Boehringer IngelheimJardiance | $75 | $46,95751 claims |
| PfizerEliquis | $630 | $45,18355 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,656 | $33,51433 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $750 | $25,66927 claims |
| Astellas Pharma US IncMyrbetriq | $528 | $17,59320 claims |
| Johnson & JohnsonXarelto | $189 | $12,61114 claims |
| AbbVieLinzess | $2,338 | $10,20214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,594 medical providers in Pennsylvania.
Other medical in Watsontown
- Jacqueline KernaghanSpringfield$426K
- Drew SodaNew Hope$220K
- Angela KapalkoPhiladelphia$123K
- Linda PerryPhiladelphia$123K
- Cory DavidsonErie$119K
- Shelley SassamanTamaqua$90K
- Meghan HoffnerBethlehem$86K
- Thomas IacovoniDanville$72K
- Scott CoxWynnewood$66K
- Sarah SmithPhiladelphia$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.